Clinical Trial

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

Completed Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-04
critical Primary endpoint(s) modified 2026-08-04
minor Completion pushed: 2023-03-30 -> 2023-06-01 2026-08-04
Trial Details
NCT Number NCT04655170
Lead Sponsor University of Tennessee Graduate School of Medicine
Collaborators: Mylan Pharmaceuticals Inc
Conditions COPD Exacerbation
Enrollment 60 participants
Start Date 2020-12-09
Primary Completion 2023-01-19 (estimated)
Study Completion 2023-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-03